Background: Lysosomal storage diseases (LSDs) are a group of rare inherited metabolic disorders, consisting of over 70 diseases that are characterised by lysosomal dysfunction. Due to their varied and progressive symptoms, LSDs have a continual impact on patients' health-related quality of life (HRQoL). Several recently published studies have provided insight into the HRQoL of individuals with LSDs. However, it is challenging to meaningfully synthesise this evidence, since studies often focus upon a particular type of LSD and / or utilise different self-report questionnaires or patient-reported outcome measures (PROMs) to assess HRQoL.

Aims: The aim of this study was to review the published literature in LSDs, to identify the PROMs which have been used to assess HRQoL and generate a conceptual map of HRQoL domains measured in individuals diagnosed with LSDs.

Methods: Three electronic databases were searched in March 2022. Primary studies of any design which utilised multi-item PROMs to assess at least one aspect of HRQoL in individuals with LSDs since 2017 were identified. Data were extracted to assess both the characteristics of each study and of the PROMs utilised within each study. The extraction of HRQoL domains and synthesis were informed by an a priori framework, inductively modified to reflect data emerging from the identified literature. Selection and extraction was undertaken independently by two reviewers; discrepancies were ratified by a third reviewer.

Results: Sixty nine studies were identified which were published 2017-2022, with a combined total of 52 PROMs (71 variants) used to assess HRQoL in individuals with LSDs. The final extracted HRQoL framework included 7 domains (Activities; Physical sensations; Autonomy; Cognition; Feelings and emotions; Self-identity; Relationships), characterised by 37 sub-domains.

Conclusions: This review highlights the breadth and variety of HRQoL domains assessed in individuals with LSDs, across three broad domains of physical, psychological and social functioning. The resultant framework and mapped PROMs will aid researchers and clinicians in the selection of PROMs to assess aspects of HRQoL in people living with LSDs, based on their conceptual coverage.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11225496PMC
http://dx.doi.org/10.1186/s13023-024-03256-0DOI Listing

Publication Analysis

Top Keywords

individuals lsds
16
proms assess
16
hrqol individuals
12
hrqol domains
12
hrqol
11
lsds
9
quality life
8
life hrqol
8
lysosomal storage
8
assess hrqol
8

Similar Publications

Background: Lysosomal storage diseases (LSDs) can be treated with intravenous enzyme replacement therapy (ERT). ERT is being administered either in specialized clinics or in the home care setting. Studies indicate that home-based ERT can be considered safe and positively effects patient reported outcomes.

View Article and Find Full Text PDF

Lysosomal storage diseases (LSDs) encompass a group of rare inherited metabolic disorders characterized by the accumulation of undegraded substrates within lysosomes, leading to multisystemic manifestations, including profound neurological involvement. This article provides a concise overview of the neurological manifestations of LSDs, with a focus on central nervous system (CNS) involvement and treatment strategies. While the paper intricacies of each LSD subtype and its associated CNS manifestations, it aims to provide a summary of the essential findings and implications.

View Article and Find Full Text PDF

Oncological Aspects of Lysosomal Storage Diseases.

Cells

October 2024

Department of Genetics, Institute of Psychiatry and Neurology, Al. Sobieskiego 9, 02-957 Warsaw, Poland.

Lysosomal storage diseases (LSDs) are caused by the deficient activity of a lysosomal hydrolase or the lack of a functional membrane protein, transporter, activator, or other protein. Lysosomal enzymes break down macromolecular compounds, which contribute to metabolic homeostasis. Stored, undegraded materials have multiple effects on cells that lead to the activation of autophagy and apoptosis, including the toxic effects of lyso-lipids, the disruption of intracellular Ca ion homeostasis, the secondary storage of macromolecular compounds, the activation of signal transduction, apoptosis, inflammatory processes, deficiencies of intermediate compounds, and many other pathways.

View Article and Find Full Text PDF
Article Synopsis
  • This study aimed to understand the relationship between Traditional Chinese Medicine syndromes and the progression of gastric diseases related to H. pylori infection by merging TCM concepts with modern molecular biology and histopathology methods.
  • It involved 203 participants, identifying key microRNA expressions (miR-499 and miR-149) and their link to various gastric conditions, revealing that miR-149 C allele is associated with lower gastric atrophy risk, while miR-499 levels correlate with higher cancer risk.
  • The findings suggest that H. pylori infection exacerbates the progression of gastric lesions, particularly in patients with specific TCM syndromes, indicating a need for targeted treatment approaches in these populations.
View Article and Find Full Text PDF

Assessment of the reliability, responsiveness, and meaningfulness of the scale for the assessment and rating of ataxia (SARA) for lysosomal storage disorders.

J Neurol

October 2024

Unité Des Ataxies Cérébelleuses, Service de Neurologie, Médiathèque Jean Jacquy, CHU-Charleroi, 6000, Charleroi, Belgium.

Article Synopsis
  • The study evaluated the Scale for the Assessment and Rating of Ataxia (SARA) for its reliability and validity in patients with neurological symptoms from lysosomal storage disorders (LSDs), particularly Niemann-Pick disease type C and GM2 Gangliosidoses.
  • Data from three clinical trials involving 122 patients and 703 visits were analyzed, focusing on retest reliability, responsiveness, and identifying meaningful changes in SARA scores through various global impression assessments.
  • Results showed high reliability (ICC of 0.95+) and minimal change in SARA scores over time, with patient interviews indicating that a one-point improvement on the SARA scale is clinically significant for patients' everyday lives.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!